THOUSAND OAKS, Calif., March 11 /PRNewswire/ -- Bone Biologics, Inc. announced today that it has received a US Patent Office Notice of Allowance of patent claims which strongly protects the formation of cartilage by the unique NELL 1 protein (UCB-1). Additional claims cover the surgical application of the NELL 1 (UCB-1) protein by several delivery agents.
The platform technology will be subject to the FDA review and approval process, including clinical trials. It is not currently approved for use in humans.
Bruce A. Hazuka, President and CEO of Bone Biologics, Inc. credited the company’s partner, the Musculoskeletal Transplant Foundation (MTF) for its ongoing financial and strategic support. “MTF is essential to our progress toward realizing the full potential of the UCB-1 protein as a platform technology.”
Musculoskeletal Transplant Foundation
Bone Biologics, Inc.
For information: Bruce A. Hazuka/Bone Biologics/818-324-2742
CONTACT: Bruce A. Hazuka, Bone Biologics, +1-818-324-2742
